Insilico Medicine Announces Industrys First Longevity Board to Accelerate AIDriven Aging Research for Drug Discovery
News Source : Associated Press
News Summary
- Insilico Medicine announces formation of industry’s first Longevity Board (Board) Board provides scientific oversight and strategic guidance for AI-enabled aging research and drug discovery.
- Board will oversee work in life models, biomarkers of aging, identification of dual-purpose targets implicated in aging, longevity and disease, and clinical development.
- Board is composed of high-profile scientists involved in aging and disease research including Dr. Andrew Adams, Group Vice President of Molecular Discovery at Lilly.
- Dr. Adams’ deep expertise in genetic medicine design and large-scale R&D operations will provide Insilico with the “Big Pharma” perspective necessary to transition experimental longevity compounds into commercially viable medicines.
CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ Insilico Medicine (Insilico, 3696.HK), a clinicalstage generative artificial intelligence (AI)driven biotechnology company, today announced the stra [+6119 chars]
Never miss a story from us, subscribe to our newsletter